Introduction     Use of extracorporeal membrane oxygenation (ECMO) (sometimes called extracorporeal life-support) is increasing in many countries. This Fast Fact will review the role of palliative care teams in caring for adults on ECMO, and their families.

The technology     The technology is fundamentally the same as a ‘heart-lung bypass machine’ used in some cardiac surgeries, although ECMO can be used for weeks instead of hours. Central venous blood is removed from the patient and pumped through a gas exchange membrane where it is oxygenated, and carbon dioxide is removed. In venovenous (VV) ECMO the blood is then reinfused into the right-sided circulation where the patient’s own heart circulates it. In venoarterial (VA) ECMO, the oxygenated blood is reinfused under arterial pressure into the aorta for circulation. Therefore, VV ECMO ‘replaces’ lung function (gas exchange); VA ECMO ‘replaces’ both heart (pump) and lung function. Initiating and providing ECMO requires specialized teams and currently is only offered at specific referral centers.

VV ECMO:  VV ECMO is used for severe hypoxemic respiratory failure; typically, the acute respiratory distress syndrome – ARDS. The best available data comes from two randomized controlled trials (CESAR and EOLIA) – pooling this data, the 90-day mortality rate of patients with severe ARDS was 36% for those treated with ECMO and 48% with best intensive care (1-3) There are observational data suggesting improved survival from ARDS during influenza and COVID-19 pandemics (4,5). In the Extracorporeal Life Support Organization’s (ELSO) international database, 57% of patients receiving VV ECMO survive to hospital discharge (6). VV ECMO has seen a 10-fold increase over the last several years (7).

VA ECMO:  VA ECMO is used for severe cardiogenic shock such as after a massive pulmonary embolus, ST- elevation myocardial infarction, congenital heart disease (CHD), or cardiac surgery.  

• Data supporting VA ECMO are less clear than VV ECMO on whether it improves outcomes compared with other advanced technologies for cardiogenic shock (e.g. ventricular-assist devices (VADs)) (8).
• The ELSO database reports hospital survival for VA ECMO is ~40% (disability rates unknown) (6).
• In a systematic review of VA ECMO use in CHD, in-hospital mortality was estimated to be 45.2% (9).
• VA ECMO is also used for sudden cardiac death patients who do not have return of spontaneous circulation after CPR.  This use is called “E-CPR” and it is also growing rapidly (10). Patients are rapidly transported to an ECMO center where ECMO is initiated to perfuse the brain and other organs while the cause of the arrest is treated. Randomized controlled trials of “E-CPR” have shown that effectiveness likely depends on patient selection factors (11,12).

Patient experience & complications    ECMO requires large caliber vascular catheters, placed in the groin or neck. Initially patients are intubated, sedated, and paralyzed. Patients who are on ECMO for many days sometimes can be awoken and even have limited mobility such sitting up in a chair or engaging in physical therapy (13,14). Continuous anticoagulation is required during ECMO to prevent thrombus formation in the circuit. Bleeding (including intracranial, gastrointestinal, and pulmonary) is the most serious complication (30-50%) and can be life-threatening (6,15). Other complications include thromboembolism, infections, acute kidney injury, and limb ischemia.

Patient trajectories     Apart from the survival statistics above, little has been written about what happens to patients receiving ECMO. Our experience is that most patients fall into 1 of 6 categories.  

1. The underlying illness recovers sufficiently for ECMO to be discontinued. These patients can have a full recovery or remain chronically critically ill, albeit off ECMO.
2. No recovery occurs, but an alternative intervention is available such as heart or lung transplantation or ventricular assist device, allowing ECMO to be discontinued.
3. The patient dies while receiving ECMO, for instance from massive intracranial bleeding.
4. ECMO is discontinued with the intent of allowing the patient to die, due to the identification of a poor functional or survival prognosis (e.g. anoxic brain injury).
5. The ECMO circuit fails (for instance, it clots off). This can lead to urgent intervention to replace the catheters and ECMO devices versus a decision to allow the patient to die. For patients with a poor underlying chance of recovery, ECMO circuit failure should trigger frank conversations about prognosis and goals, and if it is in the patient’s best interest to replace the failing ECMO system.
6. A patient becomes “stuck” on ECMO, without recovery of the underlying illness or available alternative intervention, and little chance of ever surviving without ECMO. This can cause ethical and resource utilization dilemmas if the patient/family do not agree to discontinue ECMO. There is no arbitrary time-limit to ECMO use, however its use in one patient may prevent it being used in another due to the limitation on the number of ECMO machines and personnel (16).

Palliative and end-of-life care     Fundamentally, palliative care teams can support ECMO patients/families as they would any other critically ill patient at high risk of dying: assess and clarify patient/family understanding, provide emotional and spiritual care, support patient-centered goals of care discussions, and help provide comfort care to dying patients. Educating families and preparing them early on for the possibility that a patient will not recover and ECMO will need to be discontinued is advisable. Clinicians should be prepared that most families will have no knowledge of ECMO, unlike other ICU treatments such as mechanical ventilation. Different institutions will have different protocols for discontinuing ECMO in a patient who is expected to die. The approach to symptom management in patients expected to die after ECMO discontinuation is like the removal of any other advanced life-support technology such as a ventilator or VAD. It is particularly important to ensure patients are comfortable and have adequate circulating levels of symptom medications prior to discontinuing ECMO due to the probability of rapid circulatory collapse (see Fast Fact #33, Fast Fact #34, and Fast Fact #269).

References 

1. Peek GJ, Mugford M, Tiruvoipati R, et al. CESAR Trial Collaboration. Efficacy and economic assessment of conventional ventilatory support versus extracorporeal membrane oxygenation for severe adult respiratory failure (CESAR): a multicenter randomized controlled trial. Lancet. 2009;374(9698):1351-1363.
2. Combes A, Hajage D, Capellier G,et al. Extracorporeal membrane oxygenation for severe acute respiratory distress syndrome. N Engl J Med 2018; 378:1965–1975.
3. Combes A, Peek GJ, Hajage D, et al.  ECMO for severe ARDS: systematic review and individual patient data meta-analysis. Intensive Care Medicine 2020; 46:2048-2057.
4. Noah MA, Peek GJ, Finney SJ, et al. Referral to an extracorporeal membrane oxygenation center and mortality among patients with severe 2009 influenza A (H1N1). [published online October 5, 2011]. JAMA. 2011;306(15):1659-1668.
5. Urner M, Barnett AG, Bassi GL, et al.  Venovenous extracorporeal membrane oxygenation in patients with acute COVID-19 associated respiratory failure: comparative effectiveness study. BMJ 2022; 377:e068723.
6. Extracorporeal Life Support Organization. ECLS Registry Report 2016. https://www.elso.org/Registry/Statistics/InternationalSummary.aspx. Accessed April 16, 2017.
7. Thiagarajan RR, Barbaro RP, Rycus PT, et al. Extracorporeal life support organization registry international report 2016. ASAIO Journal. 2017;63:60-67.
8. Ouweneel DM, Schotborgh VJ, Limpens J, et al. Extracorporeal life support during cardiac arrest and cardiogenic shock: a systematic review and meta-analysis. Intensive Care Med. 2016;42:1922-1934.
9. Faheem MSB, Khan AA, Cheema S, et al. Importance of extracorporeal membrane oxygenation (ECMO) in congenital heart diseases: a systematic review. Egypt Heart J 2025; 77, 70.
10. Richardson ASC, Schmidt M, Bailey M, et al.  ECMO Cardio-pulmonary resuscitation (ECPR) trends in survival from an international multicentre cohort study over 12 years. Resuscitation 2017; 112:34-40.
11. Belohlavek J, Smalcova J, Rob D, et al.  Effect of intra-arrest transport, extracorporeal cardiopulmonary resuscitation, and immediate invasive assessment and treatment on functional neurologic outcome in refractory out-of-hospital cardiac arrest: a randomized controlled trial. JAMA 2022; 327:737-747.
12. Yanopoulos D, Bartos J, Raveendran G, et al.  Advanced reperfusion strategies for patients with out-of-hospital cardiac arrest and refractory ventricular fibrillation (ARREST): a phase 2, single centre, open-label, randomized controlled trial. Lancet 2020; 396:18-7-1816.
13. Bharat A, Pham DT, Prasad SM. Ambulatory extracorporeal membrane oxygenation a surgical innovation for adult respiratory distress syndrome [published online March 9, 2016]. JAMA Surgery. Doi:10.1001/jamasurg.2015.4951.
14. Abrams D, Javidfar J, Farrand E et al. Early mobilization of patients receiving extracorporeal membrane oxygenation: a retrospective cohort study. Critical Care 2014;18:R38.
15. Mazzeffi M, Greenwood J, Tanaka K, et al. Bleeding, transfusion, and mortality on extracorporeal life support: ECLS working group on thrombosis and hemostasis. Ann Thorac Surg. 2016;101:682-9.
16. Abrams DC, Prager K, Blinderman CD, Burkart KM, Brodie D. Ethical dilemmas encountered with the use of extracorporeal membrane oxygenation in adults. Chest. 2014;145(4):876-882.

Conflicts of Interest:  None.
Authors’ Affiliations:  University of Minnesota Medical School, Minneapolis, MN (EF, JR, DAR); Methodist Hospital, St Louis Park, MN (EF); Hennepin County Medical Center, Minneapolis, MN (JR).
Version History:  Originally edited by Dr. Christopher Lawton MD; first electronically published in August 2017; reviewed and updated by Sean Marks in September 2025.